Acute or Acute-on-Chronic Liver Failure
Conditions
Interventions
HPLC group 1:peripheral intravenous injection
HPLC group 2:intraperitoneal injection
Sponsors
Xiangya Hospital Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-60 years, no gender restrictions, body mass index (BMI) between 18-35 kg/m^2, including boundary values; 2. According to clinical symptoms, signs and laboratory tests, meet the diagnostic criteria for acute or acute-on-chronic liver failure in the Chinese Guidelines for the Diagnosis and Treatment of Liver Failure (2018 Edition), and the MELD index is between 20-40. 3. Have not received cell preparation therapy in the last 6 months.
Exclusion criteria
Exclusion criteria: 1. End-stage liver disease with serious complications, including but not limited to grade IV hepatic encephalopathy, severe gastrointestinal bleeding, severe bleeding tendency, refractory ascites, hepatorenal syndrome reaching AKI stage 3, Hepatopulmonary syndrome, etc; 2. Combine serious infections that cannot be controlled 3. There are other important organ diseases, such as uncontrolled severe cardiovascular diseases (such as ventricular tachycardia, arrhythmia caused by second or third degree atrioventricular block, myocardial infarction, unstable angina, coronary Arterial disease, heart failure, etc.), uncontrolled hypertension (systolic blood pressure >=160mmHg and/or diastolic blood pressure >=100mmHg), severe respiratory diseases (active tuberculosis, chronic obstructive pulmonary disease, pulmonary interstitial disease, etc.) , Severe blood system diseases (such as myelodysplastic syndrome, thalassemia, aplastic anemia, etc.), cerebral hemorrhage, etc. 4. Have a history of severe allergic reaction or allergies to 2 or more than 2 kinds of food or drugs; 5. Serum HIV antibody positive; 6. Diagnosis of primary liver cancer or presence of liver nodules with unknown nature 7. Presence of other systemic malignancies 8. Patients with severe mental illness and cognitive dysfunction 9. Women who are pregnant, breast-feeding or planning to become pregnant 10. Participated in other clinical studies within the last 3 months; 11. Inability or unwillingness to provide informed consent; 12. The researchers believe that there are patients who cannot be included in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function;Blood coagulation function;MELD score;Liver color Doppler ultrasound;Blood routine;Urine routine;Blood chemistry;Tumor markers;Electrocardiogram;CT of lung and liver ; | — |
Countries
China
Contacts
Public ContactHuang Yan
Xiangya Hospital Central South University
Outcome results
None listed